Forbes
@forbes·2.1M subscribers·11.3K videos
Recursion Thinks AI Can Lower The High Failure Rate Of New Pharmaceutical Drugs
Posted
January 23, 2025
Views
4,180
Likes
95
Comments
3
Engagement
2.34%
January 23, 2025
4,180
95
3
2.34%
Every word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
3:39Now PlayingChris Gibson, Cofounder and CEO of Recursion, lays out how his company is building the biological data, and layering on AI, to assist in the development of new, effective therapeutics.
Subscribe to FORBES
Fuel your success with Forbes. Gain unlimited access to premium journalism, including breaking news, groundbreaking in-depth reported stories, daily digests and more. Plus, members get a front-row seat at members-only events with leading thinkers and doers, access to premium video that can help you get ahead, an ad-light experience, early access to select products including NFT drops and more:
Stay Connected
Forbes newsletters
Forbes on Facebook
Forbes Video on Twitter
Forbes Video on Instagram
More From Forbes
Forbes covers the intersection of entrepreneurship, wealth, technology, business and lifestyle with a focus on people and success.
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.
